GLAUKOS CORP (GKOS) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:GKOS - US3773221029 - Common Stock
116.37 USD
+0.15 (+0.13%)
Taking everything into account, GKOS scores 4 out of 10 in our fundamental rating. GKOS was compared to 184 industry peers in the Health Care Equipment & Supplies industry. GKOS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GKOS is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year GKOS has reported negative net income.
In the past year GKOS has reported a negative cash flow from operations.
In the past 5 years GKOS always reported negative net income.
In the past 5 years GKOS reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of GKOS (-8.77%) is better than 63.04% of its industry peers.
The Return On Equity of GKOS (-11.39%) is better than 66.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.77% | ||
| ROE | -11.39% | ||
| ROIC | N/A |
ROA(3y)-13.08%
ROA(5y)-11.18%
ROE(3y)-22.32%
ROE(5y)-18.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 76.87%, GKOS belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
In the last couple of years the Gross Margin of GKOS has declined.
GKOS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.81%
GM growth 5Y-2.05%
2. Health
2.1 Basic Checks
GKOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GKOS has been increased compared to 1 year ago.
GKOS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for GKOS has been reduced compared to a year ago.
2.2 Solvency
GKOS has an Altman-Z score of 16.92. This indicates that GKOS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 16.92, GKOS belongs to the top of the industry, outperforming 94.02% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that GKOS is not too dependend on debt financing.
GKOS has a Debt to Equity ratio of 0.09. This is in the better half of the industry: GKOS outperforms 65.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 16.92 |
ROIC/WACCN/A
WACC8.58%
2.3 Liquidity
A Current Ratio of 5.20 indicates that GKOS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.20, GKOS is in the better half of the industry, outperforming 78.80% of the companies in the same industry.
A Quick Ratio of 4.47 indicates that GKOS has no problem at all paying its short term obligations.
GKOS's Quick ratio of 4.47 is fine compared to the rest of the industry. GKOS outperforms 79.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.2 | ||
| Quick Ratio | 4.47 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 52.11% over the past year.
GKOS shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.38%.
The Revenue has been growing by 10.10% on average over the past years. This is quite good.
EPS 1Y (TTM)52.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)30.38%
Revenue growth 3Y9.26%
Revenue growth 5Y10.1%
Sales Q2Q%38.14%
3.2 Future
The Earnings Per Share is expected to grow by 27.44% on average over the next years. This is a very strong growth
GKOS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.86% yearly.
EPS Next Y55.55%
EPS Next 2Y36.66%
EPS Next 3Y32.34%
EPS Next 5Y27.44%
Revenue Next Year30.18%
Revenue Next 2Y27.13%
Revenue Next 3Y27.24%
Revenue Next 5Y27.86%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GKOS. In the last year negative earnings were reported.
Also next year GKOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as GKOS's earnings are expected to grow with 32.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.66%
EPS Next 3Y32.34%
5. Dividend
5.1 Amount
No dividends for GKOS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:GKOS (12/22/2025, 10:50:03 AM)
116.37
+0.15 (+0.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners100.67%
Inst Owner Change-7.5%
Ins Owners3.29%
Ins Owner Change-0.08%
Market Cap6.68B
Revenue(TTM)469.82M
Net Income(TTM)-87.61M
Analysts83.64
Price Target121.53 (4.43%)
Short Float %4.05%
Short Ratio1.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.11%
Min EPS beat(2)11.08%
Max EPS beat(2)39.14%
EPS beat(4)3
Avg EPS beat(4)21.48%
Min EPS beat(4)-2.27%
Max EPS beat(4)39.14%
EPS beat(8)5
Avg EPS beat(8)12.2%
EPS beat(12)8
Avg EPS beat(12)9.6%
EPS beat(16)11
Avg EPS beat(16)5.59%
Revenue beat(2)2
Avg Revenue beat(2)6.09%
Min Revenue beat(2)5.35%
Max Revenue beat(2)6.84%
Revenue beat(4)4
Avg Revenue beat(4)4.22%
Min Revenue beat(4)2.01%
Max Revenue beat(4)6.84%
Revenue beat(8)8
Avg Revenue beat(8)4.2%
Revenue beat(12)12
Avg Revenue beat(12)4.2%
Revenue beat(16)16
Avg Revenue beat(16)4.61%
PT rev (1m)0.9%
PT rev (3m)-3.53%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)-18.43%
EPS NY rev (1m)-0.74%
EPS NY rev (3m)7.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.25%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)1.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 14.22 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.68 | ||
| P/tB | 15.23 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.02
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.77
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS8.18
BVpS13.4
TBVpS7.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.77% | ||
| ROE | -11.39% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.87% | ||
| FCFM | N/A |
ROA(3y)-13.08%
ROA(5y)-11.18%
ROE(3y)-22.32%
ROE(5y)-18.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.81%
GM growth 5Y-2.05%
F-Score5
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 59.31% | ||
| Cap/Sales | 4.92% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.2 | ||
| Quick Ratio | 4.47 | ||
| Altman-Z | 16.92 |
F-Score5
WACC8.58%
ROIC/WACCN/A
Cap/Depr(3y)54.99%
Cap/Depr(5y)69.95%
Cap/Sales(3y)6.26%
Cap/Sales(5y)7.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y55.55%
EPS Next 2Y36.66%
EPS Next 3Y32.34%
EPS Next 5Y27.44%
Revenue 1Y (TTM)30.38%
Revenue growth 3Y9.26%
Revenue growth 5Y10.1%
Sales Q2Q%38.14%
Revenue Next Year30.18%
Revenue Next 2Y27.13%
Revenue Next 3Y27.24%
Revenue Next 5Y27.86%
EBIT growth 1Y23.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year65.8%
EBIT Next 3Y39.62%
EBIT Next 5Y39.25%
FCF growth 1Y41.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.76%
OCF growth 3YN/A
OCF growth 5YN/A
GLAUKOS CORP / GKOS FAQ
Can you provide the ChartMill fundamental rating for GLAUKOS CORP?
ChartMill assigns a fundamental rating of 4 / 10 to GKOS.
What is the valuation status of GLAUKOS CORP (GKOS) stock?
ChartMill assigns a valuation rating of 1 / 10 to GLAUKOS CORP (GKOS). This can be considered as Overvalued.
How profitable is GLAUKOS CORP (GKOS) stock?
GLAUKOS CORP (GKOS) has a profitability rating of 2 / 10.
Can you provide the financial health for GKOS stock?
The financial health rating of GLAUKOS CORP (GKOS) is 6 / 10.
Can you provide the expected EPS growth for GKOS stock?
The Earnings per Share (EPS) of GLAUKOS CORP (GKOS) is expected to grow by 55.55% in the next year.